NGL Fine-Chem Limited
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosph… Read more
NGL Fine-Chem Limited (NGLFINE) - Total Liabilities
Latest total liabilities as of September 2025: ₹1.84 Billion INR
Based on the latest financial reports, NGL Fine-Chem Limited (NGLFINE) has total liabilities worth ₹1.84 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NGL Fine-Chem Limited - Total Liabilities Trend (2009–2025)
This chart illustrates how NGL Fine-Chem Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
NGL Fine-Chem Limited Competitors by Total Liabilities
The table below lists competitors of NGL Fine-Chem Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Principal Capital Public Company Limited
BK:PRINC
|
Thailand | ฿5.47 Billion |
|
APEX International Financial Engineering Res & Tech Co Ltd
TWO:5210
|
Taiwan | NT$77.78 Million |
|
AB Science S.A
PINK:ABSCF
|
USA | $48.54 Million |
|
Eusu Holdings
KO:000700
|
Korea | ₩66.81 Billion |
|
DanCann Pharma A/S
PINK:DCPXF
|
USA | $1.49 Million |
|
DarioHealth Corp
NASDAQ:DRIO
|
USA | $42.79 Million |
|
Black Mammoth Metals Corporation
PINK:LQRCF
|
USA | $336.15K |
|
Brinova Fastigheter AB (publ)
ST:BRIN-B
|
Sweden | Skr12.22 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down NGL Fine-Chem Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NGL Fine-Chem Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NGL Fine-Chem Limited (2009–2025)
The table below shows the annual total liabilities of NGL Fine-Chem Limited from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹1.51 Billion | +62.49% |
| 2024-03-31 | ₹929.04 Million | +43.97% |
| 2023-03-31 | ₹645.30 Million | -12.45% |
| 2022-03-31 | ₹737.10 Million | +38.27% |
| 2021-03-31 | ₹533.08 Million | -2.47% |
| 2020-03-31 | ₹546.60 Million | +9.17% |
| 2019-03-31 | ₹500.68 Million | -12.54% |
| 2018-03-31 | ₹572.49 Million | +33.95% |
| 2017-03-31 | ₹427.38 Million | +28.37% |
| 2016-03-31 | ₹332.92 Million | -1.21% |
| 2015-03-31 | ₹337.01 Million | +7.66% |
| 2014-03-31 | ₹313.02 Million | +14.32% |
| 2013-03-31 | ₹273.81 Million | +36.33% |
| 2012-03-31 | ₹200.84 Million | +19.59% |
| 2011-03-31 | ₹167.94 Million | +43.35% |
| 2010-03-31 | ₹117.15 Million | +24.34% |
| 2009-03-31 | ₹94.22 Million | -- |